Kornimate/medical-research-clean huggingface dataset:
early diagnosis of mycosis fungoides

Conditions: Cutaneous T Cell Lymphoma

Summary: mycosis fungoides (mf) is an epidermotropic cutaneous t cell lymphoma characterized by the accumulation of cd4+ t-lymphocytes in the skin. early mf presents as erythematous patches and/or infiltrated plaques. the diagnosis of early mf is a major diagnostic challenge and the differential diagnosis with inflammatory dermatoses is often very difficult. the histopathological diagnosis is also difficult and delayed. therefore, it is important to develop biomarkers and/or a combination of biomarkers in order to improve the early diagnostic of mf. in a previous trial, investigators included 490 patients in a study aiming at identifying skin biomarkers of early mf. several activating and inhibiting kirs were found to be interesting for the skin diagnostic of mf, mainly kir2dl4 and kir3dl2. investigators later evaluated blood biomarkers in patients with erythrodermic mf and sezary syndrome (ss). this french institutional study demonstrated that the identification by pcr of a combination of 4 blood markers (cd158k/kir3dl2, pls3/t-plastin, twist and nkp46) allowed a reliable diagnosis of lymphoma in erythrodermic patients. this previously published study interestingly showed that 30% to 50% of patients with early mf expressed at least one of these biomarkers in the blood (unpublished data). other groups also recently showed that tox can be a diagnostic tool for mf. the aim of this study is to establishing an accurate blood diagnosis for early suspected mf by demonstrating that newly identified biomarkers or their combination \[5 cutaneous kir receptor markers (kir2ds1, kir2ds3, kir3dl1, kir2dl4, kir3dl2) and 5 blood biomarkers (tox, twist-1, pls3/t-plastin, kir3dl2, nkp46)\] are differentially expressed by patients with mf and patients with inflammatory dermatoses closely resembling mf lesions. statistical analysis will establish the best combination of blood biomarkers allowing the differentiation between the two groups of patients, combination that could represent a suitable diagnostic tool for early mf.


Eligibility criteria:
inclusion criteria: * patients with erythematous dermatitis of subacute evolution (\> 15 d) or chronic evolution, in the form of patches/plaques, leading to a clinically suspected cutaneous t cell lymphoma * free and informed consent signed * erythematous dermatosis, sub-acute (\> 15 days) or chronic, suspicious of mf * lack of previous hemopathy or cutaneous or extra-cutaneous lymphoma * age \> 18 years * a skin biopsy for routine diagnostic histopathological analysis at the time of inclusion * with an analysis of t-cell clonality in blood and skin at the time of inclusion exclusion criteria: * children under 18 years * sick adults under guardianship * patients refusing to participate in the research protocol * subjects not affiliated with the national health insurance system.
functional dyspepsia microbiome study

Conditions: Functional Dyspepsia

Summary: recurrent abdominal pain has long been acknowledged to be the most common chronic pain entities in children. the purpose of this study is to describe the microbiome in children with fd and to explore relationships between the microbiome and postprandial distress syndrome, anxiety scores, and mucosal biomarkers or anxiety. the specific goals of this study are to: 1) determine the frequencies and relative proportions for specific bacteria or bacteria phyla in children with fd in both duodenal mucosal specimens and stool samples. 2) determine if the frequencies or proportions of specific bacteria or bacteria phyla differ between children with and without pds. 3) determine bi-variate correlations between bacteria/phyla frequency, bacteria/phyla proportions, anxiety scores, and mucosal biomarkers, respectively.

the purpose of the current study is to describe the microbiome in children with fd and to explore relationships between the microbiome and postprandial distress syndrome, anxiety scores, and mucosal biomarkers or anxiety. specific aims 1. to determine the frequencies and relative proportions for specific bacteria or bacteria phyla in children with fd in both duodenal mucosal specimens and stool samples. 2. to determine if the frequencies or proportions of specific bacteria or bacteria phyla differ between children with and without pds. 3. to determine bi-variate correlations between bacteria/phyla frequency, bacteria/ phyla proportion, anxiety scores, and mucosal biomarkers, respectively.

Eligibility criteria:
inclusion criteria: * diagnosis of fd as determined by the gi physician in accordance with rome iii criteria * age 8-17 years inclusive * scheduled for upper endoscopy as part of routine care after failing to respond to acid suppression therapy exclusion criteria: * use of oral antibiotic or probiotic within 8 weeks prior to enrollment * use of systemic steroid or immunomodulating drug within 8 weeks of enrollment
dexmedetomidine on postoperative cognitive dysfunction and serum tau-217 protein.

Conditions: Cognitive Impairment

Summary: to assess the effect of dexmedetomidine on serum tau-217 protein and its relation to the incidence and severity of postoperative cognitive dysfunction in elderly patients undergoing major surgery under general anesthesia.

to assess the effect of dexmedetomidine on serum tau-217 protein through measuring serum tau-217 protein preoperative and postoperative period and comparing the 2 measurements , assessing the cognitive dysfunction in the elderly patients and comparing the correlation between the cognitive dysfunction with serum tau-217 level also assessing the neuroprotective effect of dexmedetomidine on postoperative cognitive dysfunction and its relation with serum tau-217 level.

Eligibility criteria:
inclusion criteria: * patients aged \> 65 years old, both genders, basal metabolic index range 18.5 to less than 35 american society of anesthesiologists i - iii with glasgow coma scale 14-15 undergoing major surgery under general anesthesia. exclusion criteria: * patients will be excluded if they refused the enrollment in our study, glasgow coma scale\<14 or if there is severe cardiac, liver or renal disease, patients have alzehimer's disease or any of the psychotic diseases, poorly educated patients and if there is any sensitivity to given drugs

Keywords: dexmedetomidine serum tau-217 protein cognitive dysfunction
study to determine the effect of efavirenz on the ecg qtcf interval in healthy subjects

Conditions: HIV/AIDS

Summary: the purpose of this study is to determine whether multiple doses of efavirenz has an effect on the qtc interval (corrected by fridericia) in cyp2b6 \*1/\*6 and \*6/\*6 healthy subjects.

cyp = cytochrome p-450 primary purpose: other: this is a phase 1 clinical pharmacology thorough qt study being conducted as a post marketing requirement

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * healthy volunteers, ages 18 to 49 years old * bmi 18 to 32 kg/m2 * women must not be pregnant or breastfeeding exclusion criteria: * a personal history of clinically relevant cardiac disease, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for torsades de pointes (eg, heart failure) * history of hypokalemia, personal history or family history of prolonged qt interval, or family history of sudden cardiac death at a young age * any of the following on 12-lead electrocardiogram (ecg) prior to study drug administration: pr ≥210 msec, qrs ≥120 msec, qt ≥500 msec, qtcf ≥450 msec, hr \<45 bpm * second or third degree heart block prior to study drug * positive urine screen for drugs of abuse * positive blood screen for hepatitis c antibody, hepatitis b surface antigen, or human immunodeficiency virus (hiv)-1, -2 antibody * any of the following lab results outside of the ranges specified below prior to dosing: alanine aminotransferase (alt) \>upper limit of normal (uln), aspartate aminotransferase (ast) \>uln, total bilirubin \>uln, direct bilirubin \>uln, creatinine \>uln, serum potassium \<lower limit of normal (lln), serum magnesium \<lln * history of allergy to moxifloxacin, efavirenz or related compounds
treatment of recurrent pregnancy loss using mesenchymal stem cells

Conditions: Recurrent Pregnancy Loss

Summary: treatment of recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

treatment of recurrent pregnancy (characterized by the presense of thin endometrium) loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

Eligibility criteria:
inclusion criteria: * female patients of reproductive age 18-49 years; * recurrent pregnancy loss without current pregnancy with thin endometrium; * unsuccessful ivf cycles due to thin endometrium; * endometrial thickness is ≤6 mm in the first and second phases of the menstrual cycle; * uterine infertility associated with endometrial hypoplasia; * the absence of genetic diseases that prevent pregnancy; * absence of taking hormonal drugs for 3 months prior to enrollment in the study. exclusion criteria: * patients with congenital malformations of the genital organs: agenesis and aplasia of the uterus, bicornuate uterus, unicornuate uterus, congenital fistula between the uterus and the digestive and urinary tracts, other congenital anomalies of the body and cervix. congenital anomaly of the body and cervix, unspecified, other specified developmental anomalies; * acute inflammatory processes in the uterus; * acute or chronic infectious and non-infectious diseases in the acute stage, including hiv, hepatitis b and c, syphilis, tuberculosis, chlamydia, myco-, ureaplasmosis, herpes, toxoplasmosis, rubella, cytomegalovirus, gonorrhea, trichomoniasis, etc.; * autoimmune diseases; * patients with malignant tumor including a history; * patients with benign tumors of the uterus and appendages; * miscarriage not associated with a thin endometrium, including immunological origin; * hyper- or hypogonadotropic insufficiency of ovarian function, hyperandrogenemia of any origin; * allergic reactions in the acute stage, established hypersensitivity to any component of the biomedical cell product; * permanent therapy with cytostatics, hormones; * mental and behavioral disorders that make it impossible for patients to participate in the study, drug and/or alcohol addiction.

Keywords: recurrent pregnancy loss, mesenchymal stem cells
bingocize: a novel mobile application for older adult health

Conditions: Activities of Daily Living; Accidental Fall; Sarcopenia; Arteriosclerosis; Diabetes Mellitus, Type 2; Hypertension; Cognitive Decline; Executive Function; Cognitive Aging

Summary: this study tests the effectiveness of using a new mobile application (bingocize®) to improve older adults' (a) adherence to an engaging exercise program, and (b) aspects of functional performance, health knowledge, dietary habits, and cognition.

health-promoting interventions designed to improve physical and mental fitness can help reduce health care costs; they can also help maintain, or even improve, older adults' quality of life. however, getting older adults to adhere to health-promoting exercise interventions remains difficult because such programs are often perceived as being time-consuming, painful, or unenjoyable. the present study's objective is to investigate the effectiveness of a novel technological exercise intervention program for older adults (bingocize); in doing so, the program has the potential to improve older adults' independence and quality of life. older adults will participate in a pre/post-intervention design with random assignment to either the experimental or one of three comparison/control groups; each group will play bingocize in a social setting with other older adults. participants in the experimental group will use the app to engage in twice-weekly bingocize sessions for twelve weeks (i.e., bingo+exercise+health education); control groups will also use the app for twelve weeks but for either health education-only, exercise-only, or bingo-only.

Eligibility criteria:
inclusion criteria: * normal or corrected normal vision * mobility (i.e., not wheelchair bound) * english is native language * minimum physical standards (e.g., ability to walk at least 10 meters) * no structured physical activity programs \>150 minutes/week in last 6 months exclusion criteria: * severe neurological impairments (e.g., parkinson's) * colorblindness * dementia
intervention to bridge the evidence-based gap in stroke care quality

Conditions: Ischemic Stroke

Summary: the purpose of this study is to evaluate whether a multifaceted quality improvement intervention can improve the adherent rate of individual and composite of evidence-based performance measures for patients with acute ischemic stroke within the first 7 days of symptom onset and reduce the incidence of a new clinical vascular event, disability, and all-cause mortality at discharge and long term clinical outcome.

study population: patients with acute ischemic stroke who were admitted to the hospital within 7 days after the initial symptom onset. program: there are multifaceted quality improvement interventions including: 1. evidence-based clinical pathway 2. standard operating procedures (sop) of performance indicators 3. a quality coordinator 4. monitoring and feedback system of performance measures endpoints: primary outcome:increase of adherence of evidence based treatment in clinical practice; secondary outcome: total mortality, disability, and major cerebrovascular events

Eligibility criteria:
inclusion criteria: * older than 18 * ischemic stroke within 7 days of the index event * direct admission based on physician evaluation or arrival through the emergency department * ability of patient or legally authorized representative to provide informed consent for 3, 6,and 12 months after initial symptom onset * eligible events were confirmed by brain ct or mri within7 days after the onset of symptoms exclusion criteria: * patients refuse to participate in this study

Keywords: acute ischemic stroke, performance measure, acute treatment
specified drug-use survey of fomepizole intravenous infusion (all-case surveillance)

Conditions: Ethylene Glycol Poisoning, Methanol Poisoning

Summary: the objective of this survey is to evaluate the safety and efficacy of fomepizole intravenous infusion in japanese patients with ethylene glycol and methanol poisonings in daily medical practice.

clinical studies for fomepizole intravenous infusion have not been conducted in japan, and there are few reports of data on drug-use, including in the literature, in japanese patients; therefore, an evaluation of the safety and efficacy of fomepizole intravenous infusion is required. this specified drug-use survey for fomepizole intravenous infusion (fomepizole intravenous infusion 1.5 g "takeda," hereinafter referred to as "the drug") was planned to evaluate the safety and efficacy of the drug in patients with ethylene glycol and methanol poisoning in daily medical practice.

Eligibility criteria:
inclusion criteria: -all patients who have been confirmed as receiving the drug exclusion criteria: -none

Keywords: pharmacotherapy
diagnostic accuracy of fine needle aspiration in parotid tumors

Conditions: Parotid Gland Neoplasms

Summary: liberal use of fine needle aspiration biopsy of parotid gland masses is controversial. all information regarding this procedure has been retrospective. our objective is to evaluate prospectively the diagnostic accuracy of the test, alone and when associated to clinical and/or radiologic data.

this is a prospective diagnostic test study. inclusion criteria are all consecutive patients with parotid gland masses referred for treatment at our center, from january 2003 to december 2007. the gold standard for the diagnosis of malignancy is the surgical pathology report of the parotidectomy specimen. cytologist and pathologist will be blind. diagnostic accuracy is determinded by bayesian analysis.

Eligibility criteria:
inclusion criteria: * consecutive patients with parotid gland masses

Keywords: parotid gland neoplasms
managed access programs for lnp023, iptacopan

Conditions: C3 Glomerulopathy (C3G); Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary: the purpose of this registration form is to list all managed access programs (maps) related to lnp023, iptacopan

* clnp023b12004m - available - managed access program (map) cohort treatment plan clnp023b12004m to provide access to iptacopan (lnp023) for complement 3 glomerulopathy in native and transplanted kidneys. * clnp023n12001m - available - managed access program (map) cohort treatment plan clnp023n12001m to provide access to iptacopan for patients with paroxysmal nocturnal hemoglobinuria (pnh).

Eligibility criteria:
inclusion criteria: * an independent request should be received from a licensed physician (in some instances from health authorities, institutions or governments). * the patient has a serious or life-threatening disease or condition and no comparable or satisfactory alternative therapy is available for diagnosis, monitoring or treatment; patient is not medically eligible for available treatment alternatives or has exhausted all available treatment options. * the patient is not eligible or able to enroll in a novartis clinical trial or continue participation in a novartis clinical trial. * there is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated. * the patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in a country (as applicable). * provision of the product will not interfere with the initiation, conduct or completion of a novartis clinical trial or overall development program. * managed access provision is allowed per local laws/regulations.

Keywords: c3 glomerulopathy (c3g) paroxysmal nocturnal hemoglobinuria (pnh) map manage access program iptacopan lnp023
individual blood pressure optimization based on cerebral autoregulation after implantation of continuous-flow lvad

Conditions: Heart-Assist Devices; Heart Failure

Summary: this study will collect retrospective and prospective clinical data regarding the principal investigator's patient population to allow for data analysis seeking basic trends and to prepare academic reports, including journal manuscripts and presentations for scientific organizations.

preoperative data will be collected as the baseline information through chart review and patient interview before the surgery as follows: patient demographics, co-morbidities, medication, preoperative laboratory results, and preoperative vital signs. intraoperative data will be collected by chart review or monitor review as follows: type of implant device, concomitant procedures, length of surgery, duration of cardiopulmonary bypass and aortic cross clamp, blood products administered hemodynamic variables, and nirs signals. postoperative data will be collected by chart review or monitor review as follows: medications, blood products administered, postoperative laboratory results, adverse events and operative mortality\*, length of mechanical ventilation, length of inotrope administered, hemodynamic variables, length of intensive care unit and hospital stay, mortality, and nirs signals. participants will receive routine standard institutional perioperative care that included invasive radial artery blood pressure monitoring. participants will be connected to the nirs monitor using sensor probes placed on the right and left sides of the forehead per routine clinical application. nirs signal monitoring will be initiated before induction of general anesthesia in the operation room for collecting baseline data, and continued during lvad implantation procedure. after implantation of lvad, continuous nirs monitoring will be carried out in the icu until termination of the invasive arterial blood pressure monitoring. for all participants enrolled in this study, all medical treatment which is provided will not deviate from the standard of clinical care, including surgery and other procedures as well as blood sample collection. the data will be reviewed routinely to seek trends. when needed to examine specific clinical issues, such as risk factors for a given complication, additional clinical data will be retrieved from the medical records. all data sets analyzed and used for presentations or publication will be anonymized to protect patient confidentiality. this study will be conducted indefinitely.

Eligibility criteria:
inclusion criteria: * male or female patients greater than or equal to 18 years old undergoing continuous-flow left ventricular assist device implantation for the clinical indications of bridge to transplant or destination therapy. exclusion criteria: * patients \< 18 years of age will be ineligible for this study.
real-life home glucose monitoring over 14 days in t2d patients with intensified therapy using insulin pump.

Conditions: Type 2 Diabetes Mellitus

Summary: this study aims at describing the glucose level by automated glucose sensors and correlating it with insulin delivery and meals over 14 days in insulin-requiring t2d patients living in real-life conditions.


Eligibility criteria:
selection criteria: * type 2 diabetes diagnosed for at least 5 years * treated with insulin pump for at least 6 months * 7.5% ≤ hba1c ≤ 10% (last available value dated less than 3 months) * having given his/her free, express and informed consent to participate to the study inclusion criteria: * 7.5% ≤ hba1c ≤ 10% (result of the dosage performed at selection visit) * daily insulin requirement ≤ 1.5u/kg/day * having been compliant to take pictures of his/her meals and snacks over the 3 days prior to the inclusion visit non-selection/non-inclusion criteria: * pregnant or breastfeeding woman * comorbidity which, in the investigator's opinion, could jeopardize the study completion * patient with difficulties to understand the study procedures or deemed unfit, by the investigator, to comply with operating instructions of cgm equipment.
cost-effectiveness of infloran (tm) in treating acute childhood diarrhea in phramongkutklao hospital

Conditions: Acute Diarrhea

Summary: the purpose of this study is to determine whether the probiotic infloran is cost-effective in treating acute childhood diarrhea.

probiotics have been proved to shorten duration of diarrhea in children; whether they are cost-effective is less clear. we'd like to validate the use of infloran, a proprietary probiotic sold in thailand, in terms of its cost-effectiveness compared to standard diarrhea care in our hospital setting.

Eligibility criteria:
inclusion criteria: * children 3 months to 6 years of age * hospitalized due to acute diarrhea exclusion criteria: * history of probiotic treatment in this episode of illness * history of use of other anti-diarrheal medications * chronic gastrointestinal disease(s) * severe dehydration * severe systemic disease(s)

Keywords: probiotic cost-effectiveness diarrhea children sum of the monetary cost of the hospitalization